CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
CAMP4 Therapeutics received EU Clinical Trial Application approval to initiate its global Phase 1/2 ASCEND trial of CMP-002 in patients with SYNGAP1-related disorder at EU sites. The approval follows July 2026 clearances from Australia's TGA and Argentina's ANMAT and a September 2026 UK MHRA authorization; the company expects to dose the first patient in 4Q 2026.
Key figures
- Drug Name
- CMP-002
- Phase Of Trial
- Phase 1/2
- Trial name
- ASCEND
- Indications note
- SYNGAP1-related disorder affects over 10,000 individuals in the US with no approved disease-modifying therapies
- First patient dosing
- 4Q 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.